Dr Albert Power is an Honorary Clinical Senior Lecturer in Renal Medicine in the Renal Section of the Division of Immunity & Inflammation in the Department of Medicine.
He graduated from Gonville & Caius College, University of Cambridge and subsequently undertook an MD in Nephrology at Imperial College London. He is a principal member of the Dialysis Research Group at the Imperial Renal & Transplant Centre, and an executive member of the international MONDO (MONitoring Dialysis Outcomes) research initiative.
He remains clinically active as Consultant Nephrologist and Clinical Lead for Haemodialysis and Renal Research at the Richard Bright Renal Centre in Bristol. He is an Honorary Senior Lecturer in the School of Clinical Sciences, University of Bristol and NIHR CRN: West of England Lead for Renal Disorders.
His specialist interests include coagulation in end-stage renal disease and the relationship between the pharmacological & dialytic modulation of the coagulation system and bleeding risk. He has an ongoing research interest in vascular access function with clinical trials and large-scale observational studies examining clinical outcomes in patients dependent on central venous catheters.
He has an active research portfolio examining the pathogenesis of cerebrovascular disease in patients with advanced renal impairment. Current work is focused on stroke pathophysiology & outcomes in patients with renal disease through regional initiatives, national studies in collaboration with the UK Renal Registry and global research through the MONDO consortium. He is conducting clinical studies that challenge traditional healthcare & dialytic paradigms to facilitate patient access to acute stroke therapies while evaluating their efficacy, and to improve post-stroke rehabilitation outcomes. In parallel with the investigation of acute cerebral vascular pathology in dialysis cohorts, Dr Power is involved in research themes directed at elucidating the determinants of cognitive dysfunction in patients on renal replacement therapies.
et al., 2019, Intravenous Iron in Patients Undergoing Maintenance Hemodialysis, New England Journal of Medicine, Vol:380, ISSN:0028-4793, Pages:447-458
et al., 2019, Increased Mortality Associated with Higher Pre-Dialysis Serum Sodium Variability: Results of the International MONitoring Dialysis Outcome Initiative., Am J Nephrol, Vol:49, Pages:1-10
et al., 2018, Association between Heights of Dialysis Patients and Outcomes: Results from a Retrospective Cohort Study of the International MONitoring Dialysis Outcomes (MONDO) Database Initiative, Blood Purification, Vol:45, ISSN:0253-5068, Pages:245-253
et al., 2018, VARIABILITY OF PRE-DIALYSIS SERUM SODIUM, A RISK FACTOR OF SURVIVAL IN HEMODIALYSIS PATIENTS: RESULTS FROM THE MONDO CONSORTIUM, 55th Congress of the European-Renal-Association (ERA) and European-Dialysis-and-Transplantation-Association (EDTA), OXFORD UNIV PRESS, ISSN:0931-0509
et al., 2017, Dialysis Access as an Area of Improvement in Elderly Incident Hemodialysis Patients: Results from a Cohort Study from the International Monitoring Dialysis Outcomes Initiative, KARGER, Pages:486-496, ISSN:0250-8095